Arcus Biosciences, Inc. (RCUS) is in Healthcare, Biotechnology, based in United States, listed on NYSE. Market cap 3.03B USD. 52-week range 14.26 to 31.73 USD. Data as of 2026-10-09.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the ...